A BILL 
To direct the Secretary of Health and Human Services, 
acting through the Director of the National Institutes 
of Health, to take certain steps to increase clinical trial 
diversity, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘NIH Clinical Trial Di-
4
versity Act of 2022’’. 
5
22:14 May 25, 2022
H7845
2 
•HR 7845 IH
SEC. 2. DIVERSITY GOALS FOR NIH FUNDED CLINICAL 
1
TRIALS. 
2
(a) APPLICATIONS.—Beginning on the date of the en-
3
actment of this Act, the Secretary of Health and Human 
4
Services, acting through the Director of the National In-
5
stitutes of Health (in this section referred to as the ‘‘Sec-
6
retary’’), shall require that a sponsor seeking to conduct 
7
a clinical trial investigating a drug or device (as those 
8
terms are defined in section 201 of the Federal Food, 
9
Drug, and Cosmetic Act (21 U.S.C. 321 et seq.)) or bio-
10
logical product (as defined in section 351(i) of the Public 
11
Health Service Act (42 U.S.C. 262(i))) that is funded by 
12
the National Institutes of Health, to submit an application 
13
(or renewal thereof) for such funding that includes— 
14
(1) clear and measurable goals for the recruit-
15
ment and retention of participants that reflect— 
16
(A) the race, ethnicity, age, and sex of pa-
17
tients with the disease or condition being inves-
18
tigated; or 
19
(B) the race, ethnicity, age, and sex of the 
20
general population of the United States if the 
21
prevalence of the disease or condition is not 
22
known; 
23
(2) a rationale for the goals specified under 
24
paragraph (1) that specifies— 
25
22:14 May 25, 2022
H7845
3 
•HR 7845 IH
(A) how investigators will calculate the 
1
number of participants for each population cat-
2
egory that reflect the population groups speci-
3
fied in paragraph (1); or 
4
(B) strategies that will be used to enroll 
5
and retain participants across the different 
6
race, ethnicity, age, and sex categories; 
7
(3) a detailed plan for how the clinical trial will 
8
achieve the goals specified under paragraph (1) that 
9
specifies— 
10
(A) the requirements for researchers, in 
11
conducting the trial, to analyze the population 
12
groups specified in paragraph (1) separately; 
13
(B) the role of community partners or 
14
community institutional review boards in re-
15
viewing the plans; and 
16
(C) how the trial will recruit a study popu-
17
lation that is— 
18
(i) in proportion to the prevalence of 
19
the disease or condition in such groups rel-
20
ative to the prevalence of the disease or 
21
condition in the overall population of the 
22
United States; 
23
(ii) in sufficient numbers to obtain 
24
clinically and statistically meaningful de-
25
22:14 May 25, 2022
H7845
4 
•HR 7845 IH
terminations of the safety and effectiveness 
1
of the drug being studied in the respective 
2
race, ethnicity, age, and sex groups; and 
3
(iii) consistent with the guidance 
4
under section 505(b)(1) of the Federal 
5
Food, Drug, and Cosmetic Act (21 U.S.C. 
6
355(b)(1)) and guidance issued by the Na-
7
tional Institutes of Health on the inclusion 
8
of women and minorities in clinical trials; 
9
(4) the sponsor’s plan for implementing, or an 
10
explanation of why the sponsor cannot implement, 
11
alternative clinical trial follow-up requirements that 
12
are less burdensome for trial participants, such as— 
13
(A) requiring fewer follow-up visits; 
14
(B) allowing phone follow-up or home vis-
15
its by nurse trial coordinators (in lieu of in-per-
16
son visits by patients); 
17
(C) allowing for online follow-up options; 
18
(D) permitting the patient’s primary care 
19
provider to perform some of the follow-up visit 
20
requirements; 
21
(E) allowing for evening and weekend 
22
hours for required follow-up visits; 
23
(F) allowing virtual or telemedicine visits; 
24
22:14 May 25, 2022
H7845
5 
•HR 7845 IH
(G) use of wearable technology to record 
1
key health parameters; and 
2
(H) use of alternate labs or imaging cen-
3
ters, which may be closer to the residence of the 
4
patients participating in the trial; and 
5
(5) the sponsor’s education and training re-
6
quirements for researchers and other individuals 
7
conducting or supporting the clinical trial with re-
8
spect to diversity and health inequities in, and the 
9
development of, curricula for healthcare profes-
10
sionals on how to participate in clinical trials as an 
11
investigator and how they can enroll patients in 
12
trials, which may include consultation with, and the 
13
review of materials made available by, such commit-
14
tees, task forces, working groups, and other entities 
15
the Director determines are appropriate, including 
16
the following: 
17
(A) The Equity Committee of the National 
18
Institutes of Health. 
19
(B) The National Advisory Council on Mi-
20
nority Health and Health Disparities. 
21
(C) The Advisory Committee on Research 
22
on Women’s Health. 
23
22:14 May 25, 2022
H7845
6 
•HR 7845 IH
(D) The Tribal Health Research Coordi-
1
nating Committee of the National Institutes of 
2
Health. 
3
(b) TERMS.— 
4
(1) IN GENERAL.—As a condition on the receipt 
5
of funding through the National Institutes of 
6
Health, as described in subsection (a), with respect 
7
to a clinical trial, the sponsor of the clinical trial 
8
shall agree to terms requiring that— 
9
(A) the aggregate demographic information 
10
of trial participants be shared on an annual 
11
basis with the Secretary while participant re-
12
cruitment and data collection in such trial is 
13
ongoing, and that such information is provided 
14
with respect to— 
15
(i) underrepresented populations, in-
16
cluding populations grouped by race, eth-
17
nicity, age, and sex; and 
18
(ii) such populations that reflect the 
19
prevalence of the disease or condition that 
20
is the subject of the clinical trial involved 
21
(as available and as appropriate to the sci-
22
entific objective for the study, as deter-
23
mined by the Director of the National In-
24
stitutes of Health); 
25
22:14 May 25, 2022
H7845
7 
•HR 7845 IH
(B) the sponsor submits to the program of-
1
ficer and grants management specialist of the 
2
specific National Institutes of Health national 
3
research institute or national center, annually 
4
or as frequently as such officer or specialist de-
5
termines necessary, the retention rate of par-
6
ticipants in the clinical trial, disaggregated by 
7
race, ethnicity, age, and sex; 
8
(C) both the clinical trial researchers and 
9
the applicant reviewers complete education and 
10
training programs on diversity in clinical trials; 
11
and 
12
(D) at the conclusion of the trial, the spon-
13
sor submits to the Secretary the number of par-
14
ticipants in the trial, disaggregated by race, 
15
ethnicity, age, and sex. 
16
(2) PRIVACY PROTECTIONS.—Any data shared 
17
under paragraph (1) may not include any individ-
18
ually identifiable information or protected health in-
19
formation with respect to clinical trial participants 
20
and shall only be disclosed to the extent allowed 
21
under Federal privacy laws. 
22
(c) EXCEPTION.—In lieu of submitting an application 
23
under subsection (a) and documentation of goals as re-
24
quired by paragraph (1) of such subsection, an applicant 
25
22:14 May 25, 2022
H7845
8 
•HR 7845 IH
may provide reasoning for why the recruitment of each 
1
of the population groups specified in paragraph (1) of sub-
2
section (a) is not necessary and why such recruitment is 
3
not scientifically justified or possible. 
4
(d) PUBLICATION.—The Secretary shall— 
5
(1) publish on a public website of the National 
6
Institutes of Health, upon receipt of an application 
7
to which subsection (a) applies— 
8
(A) a summary of the disease being tar-
9
geted in the clinical trial that is the subject of 
10
the application and the prevalence of such dis-
11
ease across race, ethnicity, age, sex, and the 
12
clinical trial representation in each such cat-
13
egory; 
14
(B) the goals specified in such application, 
15
as required by subsection (a)(1); or 
16
(C) the reasoning described in subsection 
17
(c); and 
18
(2) ensure that, in publishing information relat-
19
ing to an application under paragraph (1), the de-
20
sign of the study involved is not disclosed. 
21
(e) REMEDIATION.— 
22
(1) IN GENERAL.—In the case of a clinical trial 
23
subject to subsection (a) that fails to meet the condi-
24
tion specified pursuant to subsection (a) by such 
25
22:14 May 25, 2022
H7845
9 
•HR 7845 IH
date as may be agreed upon by the sponsor of the 
1
trial and the program officer and grants manage-
2
ment specialist of the specific National Institutes of 
3
Health national research institute or national center, 
4
the Secretary shall require the sponsor of that clin-
5
ical trial, not later than 90 days after such date oc-
6
curs— 
7
(A) to develop, in consultation with the 
8
Secretary and advocacy and community-based 
9
organizations representing individuals who are 
10
members of relevant demographic groups speci-
11
fied in subsection (a)(1), a strategic plan to in-
12
crease participation in such clinical trial of such 
13
individuals; and 
14
(B) to submit to the Secretary such stra-
15
tegic plan. 
16
(2) PUBLICATION.—The Secretary shall make 
17
publicly available on the website of the National In-
18
stitutes of Health, the strategic plan received under 
19
paragraph (1) as soon as possible after receipt. The 
20
Secretary shall ensure that, in publishing such plan 
21
under the preceding sentence, the design of the 
22
study involved is not disclosed. 
23
(3) IMPLEMENTATION.—The sponsor of the 
24
clinical trial that is the subject of the strategic plan 
25
22:14 May 25, 2022
H7845
10 
•HR 7845 IH
published under paragraph (2), shall, not later than 
1
90 days after such date as may be agreed upon by 
2
the sponsor of the trial and the appropriate program 
3
officer and grants management specialist of the Na-
4
tional Institutes of Health, implement the strategic 
5
plan. 
6
(4) TECHNICAL
ASSISTANCE.—The Secretary 
7
may provide technical assistance to a sponsor of a 
8
clinical trial, as necessary for the sponsor to meet 
9
the requirements of paragraph (3). 
10
(f) WAIVER FOR CERTAIN CLINICAL TRIALS.— 
11
(1) IN GENERAL.—In the case of a clinical trial 
12
that received funding through the National Insti-
13
tutes of Health and is ongoing as of the date of the 
14
enactment of this Act, the sponsor of such clinical 
15
trial is exempt from the requirements of (and associ-
16
ated penalties imposed by) this Act. 
17
(2) REPORT.—The Secretary shall include in 
18
the triennial report required to be submitted under 
19
section 403 of the Public Health Service Act (42 
20
U.S.C. 283), a list of all clinical trials receiving 
21
funding through the National Institutes of Health 
22
that requested and received waivers under this sec-
23
tion. 
24
(g) STUDY.— 
25
22:14 May 25, 2022
H7845
11 
•HR 7845 IH
(1) IN GENERAL.—The Comptroller General of 
1
the United States shall conduct a study that— 
2
(A) examines which actions Federal agen-
3
cies have taken to address barriers to participa-
4
tion in federally funded clinical trials by the de-
5
mographic groups specified in subsection (a)(1); 
6
and 
7
(B) identifies challenges, if any, in imple-
8
menting such actions. 
9
(2) REPORT.—Not later than 1 year after the 
10
date of the enactment of this Act, the Comptroller 
11
General of the United States shall submit to Con-
12
gress a report on the findings of the study con-
13
ducted under paragraph (1). 
14
(h) NONDISCRIMINATION.—Section 1557 of the Pa-
15
tient Protection and Affordable Care Act (42 U.S.C. 
16
18116) shall apply with respect to a clinical trial subject 
17
to subsection (a). 
18
SEC. 3. ELIMINATING COST BARRIERS. 
19
Not later than 2 years after the date of the enact-
20
ment of this Act, the Secretary of Health and Human 
21
Services, acting through the Director of the National In-
22
stitutes of Health (referred to in this section as the ‘‘Sec-
23
retary’’), shall conduct and complete a study on— 
24
22:14 May 25, 2022
H7845
12 
•HR 7845 IH
(1) the need for review of human subject regu-
1
lations specified in part 46 of title 45, Code of Fed-
2
eral Regulations (or successor regulations), and re-
3
lated guidance; 
4
(2) the modernization of such regulations and 
5
guidance to establish updated guidelines for reim-
6
bursement of out-of-pocket expenses of human sub-
7
jects, compensation of human subjects for time 
8
spent participating in the clinical trial, and incen-
9
tives for recruitment of human subjects; and 
10
(3) the need for updated safe harbor rules 
11
under section 1001.952 of title 42, Code of Federal 
12
Regulations (or successor regulations) and section 
13
1128B of the Social Security Act (commonly re-
14
ferred to as the Federal Anti-Kickback Statute (42 
15
U.S.C. 1320a–7b)) with respect to the assistance 
16
provided under this section. 
17
SEC. 4. PUBLIC AWARENESS AND EDUCATION CAMPAIGN. 
18
(a) NATIONAL CAMPAIGN.—The Secretary of Health 
19
and Human Services, acting through the Director of the 
20
National Institutes of Health and the Commissioner of 
21
Food and Drugs (referred to in this section as the ‘‘Sec-
22
retary’’) and in consultation with the stakeholders speci-
23
fied in subsection (e), shall carry out a national campaign 
24
to increase the awareness and knowledge of individuals in 
25
22:14 May 25, 2022
H7845
13 
•HR 7845 IH
the United States, including healthcare professionals, pa-
1
tients, and others, with respect to the need for diverse clin-
2
ical trials among the demographic groups identified pursu-
3
ant to section 2(a)(1). 
4
(b) REQUIREMENTS.—The national campaign con-
5
ducted under this section shall include— 
6
(1)(A) the development and distribution of writ-
7
ten educational materials; 
8
(B) the development and placing of public serv-
9
ice announcements that are intended to encourage 
10
individuals who are members of the demographic 
11
groups identified pursuant to section 2(b)(1)(A)(I) 
12
to seek to participate in clinical trials; and 
13
(C) the development of curricula for health care 
14
professionals on— 
15
(i) how to participate in clinical trials as 
16
an investigator; and 
17
(ii) how such professionals can enroll pa-
18
tients in trials; 
19
(2) such efforts as are reasonable and necessary 
20
to ensure meaningful access by consumers with lim-
21
ited English proficiency; 
22
(3) the development and distribution of best 
23
practices and training for recruiting underrep-
24
resented study populations, including a method for 
25
22:14 May 25, 2022
H7845
14 
•HR 7845 IH
sharing such best practices among clinical trial spon-
1
sors, providers, community-based organizations who 
2
assist with recruitment, and with the public; and 
3
(4) the conduct of focus groups to better under-
4
stand the concerns and fears of certain underrep-
5
resented groups who may be reluctant to participate 
6
in clinical trials. 
7
(c) HEALTH INEQUITIES.—In developing the national 
8
campaign under subsection (a), the Secretary shall recog-
9
nize and address— 
10
(1) health inequities among individuals who are 
11
members of the population groups specified in sec-
12
tion 2(b)(1)(A) with respect to access to care and 
13
participation in clinical trials; and 
14
(2) any barriers in access to care and participa-
15
tion in clinical trials that are specific to individuals 
16
who are members of such groups. 
17
(d) GRANTS.—The Secretary shall establish a pro-
18
gram to award grants to nonprofit private entities (includ-
19
ing community based organizations and faith commu-
20
nities, institutions of higher education eligible to receive 
21
funds under section 371 of the Higher Education Act of 
22
1965 (20 U.S.C. 1067q), national organizations that serve 
23
underrepresented populations, and community phar-
24
macies) to enable such entities— 
25
22:14 May 25, 2022
H7845
15 
•HR 7845 IH
(1) to test alternative outreach and education 
1
strategies to increase the awareness and knowledge 
2
of individuals in the United States, with respect to 
3
the need for diverse clinical trials that reflect the 
4
race, ethnicity, age, and sex of patients with the dis-
5
ease or condition being investigated; and 
6
(2) to cover administrative costs of such entities 
7
in assisting in diversifying clinical trials subject to 
8
section 2. 
9
(e) STAKEHOLDERS SPECIFIED.—The stakeholders 
10
specified in this subsection are the following: 
11
(1) Representatives of the Health Resources 
12
Services Administration, the Office on Minority 
13
Health of the Department of Health and Human 
14
Services, the Centers for Disease Control and Pre-
15
vention, and the National Institutes of Health. 
16
(2) Community-based resources and advocates. 
17
(f) AUTHORIZATION OF APPROPRIATIONS.—There is 
18
authorized to be appropriated to carry out this section 
19
$10,000,000 for each of fiscal years 2023 through 2026. 
20
SEC. 5. DEFINITIONS. 
21
In this Act: 
22
(1) CLINICAL TRIAL.—The term ‘‘clinical trial’’ 
23
means a research study in which one or more human 
24
subjects are prospectively assigned to one or more 
25
22:14 May 25, 2022
H7845
16 
•HR 7845 IH
interventions (which may include placebo or other 
1
control) to evaluate the effects of those interventions 
2
on health-related biomedical or behavioral outcomes. 
3
(2) SPONSOR.—The term ‘‘sponsor’’ has the 
4
meaning given such term in section 50.3 of title 21, 
5
Code of Federal Regulations (or successor regula-
6
tions). 
7
Æ 
22:14 May 25, 2022
H7845
